|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
An Open, Positive Drug-controlled, Parallel-group, Multicenter Phase II Clinical Trial of the Efficacy, Safety, and Pharmacokinetics of Flunotinib Maleate Tablets in the Treatment of Patients With Intermediate- and High-risk Myelofibrosis
This trial adopts a multicenter, open-label, positive drug parallel control clinical trial design, planning to enroll approximately 75 MF participants. Eligible participants will be stratified and assigned in a 1:1:1 ratio to the low-dose fruquintinib maleate tablet group, high-dose fruquintinib maleate tablet group, or the ruxolitinib tablet group. Stratification factors include the Dynamic International Prognostic Scoring System (DIPSS) risk classification (intermediate-2 and high risk)
A randomized, double-blind, placebo-controlled, dose-escalating, single-dose, oral phase I clinical study of the safety, tolerability, and pharmacokinetics of flunotinib maleate tablets in healthy adult subjects in China.
Start Date13 Mar 2024 |
Sponsor / Collaborator- |
100 Clinical Results associated with FLT3 x CDK6 x JAK2
100 Translational Medicine associated with FLT3 x CDK6 x JAK2
0 Patents (Medical) associated with FLT3 x CDK6 x JAK2
